Literature DB >> 27298416

Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease.

Richard L Bowen1, Tracy Butler2, Craig S Atwood3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27298416      PMCID： PMC5019750          DOI： 10.1200/JCO.2015.66.3997

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Ketoconazole-induced stimulation of gonadotropin output in men: basis for a potential test of gonadotropin reserve.

Authors:  A R Glass
Journal:  J Clin Endocrinol Metab       Date:  1986-11       Impact factor: 5.958

2.  A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.

Authors:  Richard L Bowen; George Perry; Chengjie Xiong; Mark A Smith; Craig S Atwood
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Effect of the antiandrogen flutamide on pituitary LH content and release.

Authors:  M L Sardañons; M A de las Heras; R S Calandra; A R Solano; E J Podestá
Journal:  Neuroendocrinology       Date:  1989-08       Impact factor: 4.914

Review 4.  Reproductive hormones modulate oxidative stress in Alzheimer's disease.

Authors:  Anna M Barron; Stephanie J Fuller; Giuseppe Verdile; Ralph N Martins
Journal:  Antioxid Redox Signal       Date:  2006 Nov-Dec       Impact factor: 8.401

5.  Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease.

Authors:  Anthony V D'Amico; Michelle H Braccioforte; Brian J Moran; Ming-Hui Chen
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jan-Mar       Impact factor: 2.703

Review 6.  Gonadotropin-releasing hormone and its analogs.

Authors:  P M Conn; W F Crowley
Journal:  Annu Rev Med       Date:  1994       Impact factor: 13.739

7.  [Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate].

Authors:  C Nedelec; S Ragot; J Irani; C Pires; R Gil; B Doré
Journal:  Prog Urol       Date:  2008-11-18       Impact factor: 0.915

8.  Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition.

Authors:  Richard L Bowen; Giuseppe Verdile; Tianbing Liu; Albert F Parlow; George Perry; Mark A Smith; Ralph N Martins; Craig S Atwood
Journal:  J Biol Chem       Date:  2004-02-09       Impact factor: 5.157

9.  Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

Authors:  Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

10.  Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.

Authors:  J Verhelst; L Denis; P Van Vliet; H Van Poppel; J Braeckman; P Van Cangh; J Mattelaer; D D'Hulster; C Mahler
Journal:  Clin Endocrinol (Oxf)       Date:  1994-10       Impact factor: 3.478
  10 in total
  3 in total

Review 1.  Epilepsy, depression, and growth hormone.

Authors:  Tracy Butler; Patrick Harvey; Lila Cardozo; Yuan-Shan Zhu; Adam Mosa; Emily Tanzi; Fahad Pervez
Journal:  Epilepsy Behav       Date:  2019-02-14       Impact factor: 2.937

2.  Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al.

Authors:  Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544

3.  Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer.

Authors:  Gregory L Branigan; Georgina Torrandell-Haro; Maira Soto; Edward P Gelmann; Francesca Vitali; Kathleen E Rodgers; Roberta Diaz Brinton
Journal:  Cancer Med       Date:  2022-03-16       Impact factor: 4.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.